{
    "hands_on_practices": [
        {
            "introduction": "Many inherited metabolic disorders, particularly lysosomal storage diseases, can be understood through a simple yet powerful kinetic model. The core principle is an imbalance between the rate at which a substance enters a cellular compartment and the rate at which it is degraded. This first exercise  challenges you to derive this fundamental relationship from first principles by modeling substrate turnover within a lysosome as a first-order ordinary differential equation. By solving this equation, you will build a quantitative intuition for how an enzymatic deficiency directly causes a pathological increase in the steady-state level of a stored substance.",
            "id": "4393578",
            "problem": "A lysosome receives a macromolecular substrate $S$ at a constant influx rate $v_{\\text{in}}$ and removes it through a single catabolic enzyme that follows first-order kinetics with rate constant $k_d$. In a well-mixed compartment, conservation of mass states that the rate of change of the amount of $S$ equals influx minus efflux. First-order kinetics implies that the efflux rate is proportional to the amount present.\n\nSuppose a genetic deficiency reduces the enzyme’s effective rate constant to a fraction $\\beta$ of its normal value, with $0 < \\beta < 1$. Let the initial amount be $S(0)=S_0$. Starting from the conservation law and the definition of first-order kinetics, write the governing ordinary differential equation (ODE) for $S(t)$ under deficiency and solve it for $S(t)$ using standard methods. Then, using the definition of steady-state as the condition where the time derivative vanishes and equivalently as the long-time limit $t \\to \\infty$, determine how the deficiency alters the steady-state amount relative to normal.\n\nFor grading, report your final result as a single closed-form analytic expression for the deficient-state time course $S_{\\text{def}}(t)$ in terms of $v_{\\text{in}}$, $k_d$, $\\beta$, $S_0$, and $t$. Do not include units in your final expression.",
            "solution": "The appropriate starting points are the conservation of mass in a well-mixed compartment and the definition of first-order kinetics. Conservation of mass implies that the rate of change of the amount of substrate $S$ is the difference between the influx and efflux. First-order kinetics states that the efflux rate is proportional to the amount present with proportionality constant given by the effective degradation rate constant.\n\nUnder normal conditions, the efflux rate is $k_d S$. Under deficiency, the enzyme’s effective rate constant is reduced to $\\beta k_d$ with $0<\\beta<1$, so the efflux becomes $\\beta k_d S$. With a constant influx $v_{\\text{in}}$, the ordinary differential equation (ODE) for the deficient case therefore is\n$$\n\\frac{dS}{dt} \\;=\\; v_{\\text{in}} \\;-\\; \\beta k_d\\, S.\n$$\nThis is a linear first-order ODE. To solve for $S(t)$ with initial condition $S(0)=S_0$, we write it in standard linear form:\n$$\n\\frac{dS}{dt} + \\beta k_d\\, S \\;=\\; v_{\\text{in}}.\n$$\nThe integrating factor method uses the integrating factor\n$$\n\\mu(t) \\;=\\; \\exp\\!\\left(\\int \\beta k_d \\, dt\\right) \\;=\\; \\exp(\\beta k_d\\, t).\n$$\nMultiplying both sides of the ODE by $\\exp(\\beta k_d\\, t)$ gives\n$$\n\\exp(\\beta k_d t)\\,\\frac{dS}{dt} + \\beta k_d\\, \\exp(\\beta k_d t)\\, S \\;=\\; v_{\\text{in}}\\, \\exp(\\beta k_d t).\n$$\nRecognizing the left-hand side as the derivative of a product, we have\n$$\n\\frac{d}{dt}\\!\\left[S(t)\\, \\exp(\\beta k_d t)\\right] \\;=\\; v_{\\text{in}}\\, \\exp(\\beta k_d t).\n$$\nIntegrating both sides with respect to $t$ yields\n$$\nS(t)\\, \\exp(\\beta k_d t) \\;=\\; \\int v_{\\text{in}}\\, \\exp(\\beta k_d t)\\, dt \\;+\\; C \\;=\\; \\frac{v_{\\text{in}}}{\\beta k_d}\\, \\exp(\\beta k_d t) \\;+\\; C,\n$$\nwhere $C$ is the constant of integration. Solving for $S(t)$,\n$$\nS(t) \\;=\\; \\frac{v_{\\text{in}}}{\\beta k_d} \\;+\\; C\\, \\exp(-\\beta k_d t).\n$$\nUse the initial condition $S(0)=S_0$ to determine $C$:\n$$\nS_0 \\;=\\; \\frac{v_{\\text{in}}}{\\beta k_d} \\;+\\; C \\;\\;\\Rightarrow\\;\\; C \\;=\\; S_0 \\;-\\; \\frac{v_{\\text{in}}}{\\beta k_d}.\n$$\nSubstituting back gives the deficient-state time course:\n$$\nS_{\\text{def}}(t) \\;=\\; \\frac{v_{\\text{in}}}{\\beta k_d} \\;+\\; \\left(S_0 \\;-\\; \\frac{v_{\\text{in}}}{\\beta k_d}\\right)\\, \\exp(-\\beta k_d t).\n$$\n\nTo determine the steady-state under deficiency using first principles, we set the time derivative to zero (steady-state is no net accumulation) in the ODE:\n$$\n0 \\;=\\; v_{\\text{in}} \\;-\\; \\beta k_d\\, S_{\\text{ss,def}} \\;\\;\\Rightarrow\\;\\; S_{\\text{ss,def}} \\;=\\; \\frac{v_{\\text{in}}}{\\beta k_d}.\n$$\nAlternatively, take the long-time limit of the time-course solution:\n$$\n\\lim_{t\\to\\infty} S_{\\text{def}}(t) \\;=\\; \\frac{v_{\\text{in}}}{\\beta k_d},\n$$\nsince $\\exp(-\\beta k_d t)\\to 0$ as $t\\to\\infty$. For comparison, the normal steady-state (when $\\beta=1$) is $S_{\\text{ss,norm}}=\\frac{v_{\\text{in}}}{k_d}$. The deficiency increases steady-state by a factor of $\\frac{1}{\\beta}$, which is consistent with pathological intracellular accumulation when $\\beta<1$.\n\nPer the problem’s instruction, the final reported result should be the closed-form expression for $S_{\\text{def}}(t)$.",
            "answer": "$$\\boxed{\\frac{v_{\\text{in}}}{\\beta k_d}+\\left(S_0-\\frac{v_{\\text{in}}}{\\beta k_d}\\right)\\exp(-\\beta k_d t)}$$"
        },
        {
            "introduction": "Intracellular accumulation is not always due to an inherited genetic defect; it is often an acquired condition resulting from exposure to toxins or metabolic stress. A classic clinical example is hepatic steatosis, or fatty liver, where triglyceride accumulation is driven by factors like alcohol consumption. This practice problem  extends the mass balance principle to a more complex, multi-component biological system. By accounting for the rates of fatty acid uptake, synthesis, oxidation, and export, you will quantitatively determine how a specific perturbation—the inhibition of $\\beta$-oxidation by ethanol—disrupts homeostasis and leads to pathological lipid accumulation in a hepatocyte.",
            "id": "4393562",
            "problem": "A hepatocyte accumulates cytosolic triglyceride mass $M(t)$ based on inflows, outflows, generation, and consumption. Consider the following experimentally measured baseline rates for fatty acids (FA) and triglyceride handling in a standardized liver cell culture: FA uptake rate $v_{\\text{FA uptake}}$, mitochondrial $\\beta$-oxidation rate $v_{\\beta\\text{-oxidation}}$, Very Low Density Lipoprotein (VLDL) export rate $v_{\\text{VLDL export}}$, and de novo lipogenesis rate $v_{\\text{lipogenesis}}$. Ethanol exposure increases the cytosolic reduced nicotinamide adenine dinucleotide (NADH) burden and decreases $v_{\\beta\\text{-oxidation}}$ by a fraction $0.40$, with other rates unchanged over the short term.\n\nGiven the baseline values $v_{\\text{FA uptake}} = 5.6$, $v_{\\beta\\text{-oxidation}} = 4.0$, $v_{\\text{VLDL export}} = 1.1$, and $v_{\\text{lipogenesis}} = 0.9$ (all in nanomoles per minute), use conservation of mass for the intracellular triglyceride pool $M(t)$ to compute the net triglyceride accumulation rate $\\frac{dM}{dt}$ under ethanol exposure. Round your answer to three significant figures. Express your final rate in nanomoles per minute (nmol/min).",
            "solution": "The problem requires the calculation of the net triglyceride accumulation rate, $\\frac{dM}{dt}$, in a hepatocyte under ethanol exposure. The fundamental principle governing this process is the conservation of mass. The rate of change of the intracellular triglyceride mass, $M(t)$, is equal to the sum of all rates of processes that generate or contribute to the triglyceride pool, minus the sum of all rates of processes that consume or remove triglycerides from the pool.\n\nLet us define the source and sink terms for the hepatocyte lipid pool. The problem provides four key metabolic rates.\nThe sources of fatty acids, which are the precursors for triglyceride synthesis, are:\n1. Fatty acid uptake from the extracellular environment, with rate $v_{\\text{FA uptake}}$.\n2. De novo lipogenesis (synthesis of new fatty acids), with rate $v_{\\text{lipogenesis}}$.\n\nThe sinks for fatty acids or the resulting triglycerides are:\n1. Mitochondrial $\\beta$-oxidation (breakdown of fatty acids for energy), with rate $v_{\\beta\\text{-oxidation}}$. This pathway competes with triglyceride synthesis for the common substrate pool of fattyacyl-CoA. Therefore, it represents a sink in the mass balance.\n2. Export of triglycerides from the cell as Very Low Density Lipoproteins (VLDL), with rate $v_{\\text{VLDL export}}$. This is a direct removal of triglycerides from the intracellular pool.\n\nAssuming all rates are provided in consistent and comparable units (i.e., nanomoles of fatty acid equivalents per minute), we can formulate the mass balance equation for the net rate of triglyceride accumulation, $\\frac{dM}{dt}$, as follows:\n$$\n\\frac{dM}{dt} = (\\text{Sources of Fatty Acids}) - (\\text{Sinks for Fatty Acids and Triglycerides})\n$$\n$$\n\\frac{dM}{dt} = (v_{\\text{FA uptake}} + v_{\\text{lipogenesis}}) - (v_{\\beta\\text{-oxidation}} + v_{\\text{VLDL export}})\n$$\nThis equation represents the net flux of lipids within the hepatocyte, which, under conditions of positive balance, results in the accumulation of triglycerides.\n\nThe problem provides the following baseline rates:\n- $v_{\\text{FA uptake}} = 5.6 \\, \\text{nmol/min}$\n- $v_{\\beta\\text{-oxidation}} = 4.0 \\, \\text{nmol/min}$\n- $v_{\\text{VLDL export}} = 1.1 \\, \\text{nmol/min}$\n- $v_{\\text{lipogenesis}} = 0.9 \\, \\text{nmol/min}$\n\nEthanol exposure alters these dynamics. The problem states that ethanol exposure increases the cytosolic NADH burden, which in turn decreases the rate of mitochondrial $\\beta$-oxidation, $v_{\\beta\\text{-oxidation}}$, by a fraction of $0.40$. The other rates are stated to be unchanged in the short term.\n\nLet's calculate the new rate of $\\beta$-oxidation, which we will denote as $v'_{\\beta\\text{-oxidation}}$. A decrease by a fraction of $0.40$ means the new rate is $1 - 0.40 = 0.60$ times the original rate.\n$$\nv'_{\\beta\\text{-oxidation}} = v_{\\beta\\text{-oxidation}} \\times (1 - 0.40) = 4.0 \\, \\text{nmol/min} \\times 0.60 = 2.4 \\, \\text{nmol/min}\n$$\nThe other rates remain:\n- $v'_{\\text{FA uptake}} = v_{\\text{FA uptake}} = 5.6 \\, \\text{nmol/min}$\n- $v'_{\\text{VLDL export}} = v_{\\text{VLDL export}} = 1.1 \\, \\text{nmol/min}$\n- $v'_{\\text{lipogenesis}} = v_{\\text{lipogenesis}} = 0.9 \\, \\text{nmol/min}$\n\nNow, we can substitute these new rates into our mass balance equation to find the triglyceride accumulation rate under ethanol exposure, $(\\frac{dM}{dt})_{\\text{ethanol}}$:\n$$\n\\left(\\frac{dM}{dt}\\right)_{\\text{ethanol}} = (v'_{\\text{FA uptake}} + v'_{\\text{lipogenesis}}) - (v'_{\\beta\\text{-oxidation}} + v'_{\\text{VLDL export}})\n$$\nSubstituting the numerical values:\n$$\n\\left(\\frac{dM}{dt}\\right)_{\\text{ethanol}} = (5.6 + 0.9) - (2.4 + 1.1) \\, \\text{nmol/min}\n$$\nFirst, we compute the sum of the source terms and sink terms:\n$$\n\\text{Sources} = 5.6 + 0.9 = 6.5 \\, \\text{nmol/min}\n$$\n$$\n\\text{Sinks} = 2.4 + 1.1 = 3.5 \\, \\text{nmol/min}\n$$\nNow, we calculate the net rate:\n$$\n\\left(\\frac{dM}{dt}\\right)_{\\text{ethanol}} = 6.5 - 3.5 = 3.0 \\, \\text{nmol/min}\n$$\nThe calculated net triglyceride accumulation rate is $3.0 \\, \\text{nmol/min}$. The problem specifies that the answer should be rounded to three significant figures. While the rules of significant figures for addition with the given data would suggest a result with one decimal place ($3.0$, two significant figures), we must adhere to the explicit instruction. To express the value $3.0$ with three significant figures, we write it as $3.00$.",
            "answer": "$$\n\\boxed{3.00}\n$$"
        },
        {
            "introduction": "Understanding the mechanisms of accumulation is the first step; devising strategies to reverse it is the ultimate goal of translational research. Rather than simply replacing a missing enzyme, modern therapeutic approaches often aim to stimulate the cell's own clearance pathways. This final exercise  shifts the focus from quantitative modeling to qualitative, systems-level prediction in the context of Pompe disease, a glycogen storage disorder. You are asked to integrate your knowledge of lysosomal biogenesis, autophagy, and master transcriptional regulators like TFEB to predict the cellular outcome of a therapy designed to boost the entire clearance system, providing insight into the logic behind cutting-edge drug development.",
            "id": "4393521",
            "problem": "A research team models glycogen storage disease type II (Pompe disease) using differentiated human skeletal myotubes lacking acid alpha-glucosidase (GAA). They treat cells with a small molecule that drives Transcription Factor EB (TFEB) into the nucleus (for example, by inhibiting mechanistic Target of Rapamycin Complex $1$ (mTORC$1$)), and then measure markers of lysosomal biogenesis, autophagic flux, and glycogen burden. Using only fundamental definitions and well-tested facts, predict the most likely constellation of changes caused by TFEB activation in this disease context.\n\nBase facts you may use:\n- Lysosomes degrade macromolecules via acid hydrolases; lysosomal mass and function are regulated transcriptionally by TFEB, which binds Coordinated Lysosomal Expression and Regulation (CLEAR) elements to upregulate genes encoding lysosomal membrane proteins (for example, lysosomal-associated membrane protein $1$ (LAMP$1$)), hydrolases, proton pumps, and autophagy machinery.\n- Autophagy is a multi-step process including induction, cargo sequestration, autophagosome–lysosome fusion, and degradation. Autophagic flux is inferred from changes in microtubule-associated protein $1$ light chain $3$ (LC$3$) and sequestosome $1$ (p$62$) at baseline and after transient blockade of lysosome acidification or fusion (for example, bafilomycin A$1$): increased flux typically shows lower steady-state LC$3$-II and p$62$, with larger accumulation of these proteins upon acute lysosomal blockade.\n- In Pompe disease, lysosomal glycogen accumulates due to GAA deficiency; autophagic buildup can occur in skeletal muscle fibers. TFEB can also promote lysosomal exocytosis through channels such as mucolipin transient receptor potential cation channel $1$ (MCOLN$1$) and calcium (Ca$^{2+}$) signaling.\n\nWhich option best describes the expected effects of TFEB activation on lysosomal biogenesis and clearance of storage material in these GAA-deficient myotubes?\n\nA. Increased nuclear TFEB with upregulation of CLEAR network genes; increased LAMP$1$-positive lysosomes; enhanced autophagic flux (lower steady-state LC$3$-II and p$62$, but greater LC$3$-II and p$62$ accumulation after bafilomycin A$1$); net reduction in intracellular glycogen inclusions by Periodic Acid–Schiff staining; and a modest rise in extracellular glycogen due to increased lysosomal exocytosis.\n\nB. Decreased lysosomal biogenesis with reduced LAMP$1$ expression; suppressed autophagic flux (higher steady-state LC$3$-II and p$62$ with minimal change after bafilomycin A$1$); marked increase in intracellular glycogen accumulation; and reduced extracellular glycogen.\n\nC. Increased autophagy induction but impaired autophagosome–lysosome fusion as a direct effect of TFEB; increased steady-state LC$3$-II and p$62$; increased lysosomal number but worsening glycogen storage due to blockade at the fusion step; no change in extracellular glycogen.\n\nD. No change in lysosomal gene expression; direct upregulation of cytosolic glycogen phosphorylase by TFEB leading to complete normalization of glycogen without altering LC$3$-II, p$62$, LAMP$1$, or lysosomal exocytosis.\n\nE. Increased lysosomal biogenesis with higher LAMP$1$ and more autophagosomes, but because the enzyme defect persists, inevitable worsening of intracellular glycogen with no improvement in autophagic flux and no change in extracellular glycogen release.",
            "solution": "We begin from core definitions and widely accepted facts:\n\n- TFEB is a master transcriptional regulator of the lysosomal-autophagy system. When dephosphorylated and translocated to the nucleus (for example, during mTORC$1$ inhibition), it binds CLEAR elements to drive coordinated upregulation of lysosomal membrane proteins (for example, LAMP$1$), acid hydrolases, vacuolar ATPase subunits, and autophagy genes. The first-order prediction is an increase in lysosomal biogenesis and an enhancement of the autophagy–lysosome pathway’s capacity.\n\n- Autophagic flux can be inferred by monitoring LC$3$ and p$62$. Increased flux, under steady-state conditions, typically lowers LC$3$-II and p$62$ due to more efficient delivery to, and degradation within, lysosomes. Upon acute lysosomal blockade (for example, with bafilomycin A$1$), systems with higher flux will show a larger accumulation of LC$3$-II and p$62$ than systems with low flux, because more cargo is being produced and normally cleared.\n\n- In Pompe disease, the primary defect is in lysosomal glycogen degradation due to lack of GAA. This causes lysosomal glycogen accumulation and can secondarily disturb autophagic flux in muscle fibers. However, TFEB activation not only increases lysosomal number and expression of associated machinery, but also promotes autophagosome–lysosome fusion and lysosomal exocytosis via MCOLN$1$ and Ca$^{2+}$ signaling. Even if the intrinsic enzymatic defect remains, enhanced exocytosis and overall pathway throughput can reduce the intracellular burden by exporting contents and by clearing autophagic buildup, although enzyme deficiency prevents complete biochemical correction.\n\nUsing these principles, predicted consequences of TFEB activation in GAA-deficient myotubes include:\n- Increased nuclear TFEB and expression of CLEAR network genes (for example, LAMP$1$), resulting in more lysosomes.\n- Enhanced autophagic flux: at baseline, lower steady-state LC$3$-II and p$62$ due to faster clearance; with bafilomycin A$1$, a larger rebound accumulation of LC$3$-II and p$62$ compared to untreated cells, indicating greater flux.\n- Net reduction of intracellular glycogen inclusions (for example, by Periodic Acid–Schiff staining), mediated by improved autophagic handling and lysosomal exocytosis, though not a complete cure without GAA restoration.\n- A modest increase in extracellular glycogen or glycogen-derived material due to increased lysosomal exocytosis.\n\nNow, evaluate each option:\n\nA. This option aligns with TFEB biology. It predicts increased lysosomal biogenesis (LAMP$1$-positive organelles), enhanced autophagic flux as evidenced by decreased steady-state LC$3$-II and p$62$ but increased accumulation upon bafilomycin A$1$, and a reduction in intracellular glycogen due to augmented pathway capacity and lysosomal exocytosis. It also anticipates some increase in extracellular glycogen, consistent with TFEB-driven exocytosis via MCOLN$1$ and Ca$^{2+}$. Verdict — Correct.\n\nB. This describes the opposite of TFEB activation: decreased lysosomal biogenesis, suppressed autophagic flux, and worsened storage, with reduced extracellular release. TFEB does not repress the CLEAR network; it activates it. Verdict — Incorrect.\n\nC. It claims TFEB directly impairs autophagosome–lysosome fusion. TFEB in fact coordinately upregulates genes that promote fusion and lysosomal function; increased LC$3$-II and p$62$ at steady state with fusion blockade would be expected from fusion inhibitors, not TFEB activation. While Pompe muscle can have fusion/autophagic defects, TFEB activation does not directly cause such impairment; it tends to alleviate it. Verdict — Incorrect.\n\nD. This asserts no change in lysosomal genes and a direct TFEB-driven upregulation of cytosolic glycogen phosphorylase leading to full correction. TFEB regulates lysosomal and autophagy genes; it is not known as a primary transcriptional activator of cytosolic glycogenolysis, and complete normalization without restoring GAA is unlikely. Verdict — Incorrect.\n\nE. It acknowledges increased lysosomal biogenesis but asserts inevitable worsening of glycogen with no improvement in flux and no change in exocytosis. This ignores TFEB’s role in enhancing flux and promoting lysosomal exocytosis. Although the enzymatic defect persists, TFEB activation typically reduces, not worsens, intracellular burden by increasing capacity and exocytosis. Verdict — Incorrect.\n\nTherefore, option A best matches predictions derived from TFEB’s established regulatory roles and the pathophysiology of Pompe disease.",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}